SCHEMBL139347

SCHEMBL139347

Fc1nc(Cc2ccccc2)cc(Nc2nc3ccc(Cl)nc3s2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 12/20 0.50
LCK P06239 12/20 0.50
ITK Q08881 12/20 0.50
IRAK4 Q9NWZ3 2/20 0.43
BTK Q06187 2/20 0.42
EGFR P00533 1/20 0.42
INSR P06213 1/20 0.42
SRC P12931 1/20 0.42
TEC P42680 1/20 0.42
TXK P42681 1/20 0.42
BMX P51813 1/20 0.42
LRRK2 Q5S007 1/20 0.42
CAMKK2 Q96RR4 1/20 0.42
ALDH1A1 P00352 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HCK P08631 1/20 0.35
CHRNA7 P36544 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL142496 0.87 LCK (0.65) AURKBLCKITKIRAK4BTK
SCHEMBL138318 0.85 LCK (0.66) AURKBLCKITKIRAK4BTK
SCHEMBL139226 0.84 ITK (0.64) AURKBLCKITKIRAK4BTK
SCHEMBL141266 0.79 AURKB (0.51) AURKBLCKITKIRAK4BTK
SCHEMBL141186 0.79 AURKB (0.51) AURKBLCKITKIRAK4BTK
SCHEMBL140143 0.79 AURKB (0.65) AURKBLCKITKIRAK4BTK
SCHEMBL179062 0.79 AURKB (0.50) AURKBLCKITKIRAK4BTK
SCHEMBL140612 0.79 ITK (0.81) AURKBLCKITKIRAK4BTK
SCHEMBL140611 0.79 ITK (0.81) AURKBLCKITKIRAK4BTK
SCHEMBL114070 0.78 IRAK4 (0.45) AURKBLCKITKIRAK4BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK AURKB 53/4885LCK 189/4885ITK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.